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Abstract 
Background: Bone metastases are common in patients with advanced cancer. Bisphosphonates (BPs) could prevent 
or delay the development of skeleton-related events (SREs). The present study aimed to identify the clinical features of 
and treatment strategies for Chinese patients with bone metastases.
Methods: Consecutive cancer patients who had bone metastases and received BP treatment were enrolled. A ques-
tionnaire was developed to collect the patients’ clinical data, as well as information on the diagnosis and manage-
ment of bone metastases. Physicians’ awareness of the guidelines and knowledge of the application of BP were also 
assessed.
Results: A total of 3223 patients with lung cancer (36.5%), breast cancer (30.9%), prostate cancer (8.5%), and gas-
trointestinal cancer (5.7%) were included in this study. The sites of bone metastases were the thoracic spine (56.0 %), 
lumbar spine (47.1%), ribs (32.6%), and pelvis (23.2%). The SRE frequency was the highest in patients with multiple 
myeloma (36.6%), followed by those with lung cancer (25.9%), breast cancer (20.2%), prostate cancer (18.2%), and gas-
trointestinal cancer (17.3%). Irradiation to the bone was the most frequent SRE (58% in lung cancer patients, 45% in 
breast cancer patients, and 48% in prostate cancer patients). Our survey also showed that 45.5% of patients received 
BP within 3 months after their diagnosis of bone metastases, whereas the remaining 54.5% of patients did not receive 
BP treatment until at least 3 months after their diagnosis of bone metastases. The SRE frequency in the former group 
was significantly lower than that in the latter group (4.0% vs. 42.3%, P < 0.05). In patients with more than 6 months 
of continuous BP treatment, the mean time to the first SRE was significantly longer than that in patients with less 
than 6 months of continuous BP treatment (7.2 vs. 3.4 months, P < 0.05). In addition, 12.2% of the physicians were 
not aware of the efficacy of BP in preventing and delaying SRE. Only half (52.3%) of the physicians agreed that the BP 
treatment should persist for at least 6 months unless it was intolerable.
Conclusions: Our study suggested that prompt and persistent BP treatment was associated with a reduced risk of 
SREs. However, our survey also revealed that the proper application of BP was not as common as expected in China.
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Background
Advanced cancer is often associated with metastasis, 
and the bone is a common metastatic site [1, 2]. Bone 
metastases are frequently associated with certain types 
of cancer. For example, bone metastases occur in 70% 
of breast or prostate cancer patients and in 40% of lung 
cancer patients [2]. Bone metastases usually result in 
reduced survival of patients with advanced cancer [3, 4]. 
Furthermore, bone metastases also substantially affect 
the patient’s quality of life (QoL) due to skeleton-related 
events (SREs), such as pathologic fractures, the need for 
bone radiotherapy and surgery, spinal cord compression, 
and hypercalcemia.
The prevention and delay of SREs and improvements 
in the patient’s QoL are the primary goals for the clini-
cal management of bone metastases. Due to the diversity 
and complexity of the skeletal complications, the treat-
ment of bone metastases often involves multidisciplinary 
approaches. The use of bisphosphonates (BPs) has played 
an essential role in the management of bone metasta-
ses. As analogues of endogenous pyrophosphate, which 
regulates mineral turnover in the bone, BPs bind to the 
hydroxyapatite crystals in the bone and inhibit bone 
resorption. Previous studies have shown that BPs can 
prevent and delay SREs, thus reducing the risk of skeletal 
complications in patients with bone metastases [5–8]. In 
particular, the third-generation BPs, which are superior 
to first- or second-generation BPs, have shown signifi-
cantly improved efficacy and have been widely used for 
the treatment of bone metastases [9–12]. Therefore, the 
guidelines have recommended the application of BPs as a 
standard therapy for bone metastases [3, 13–15].
To improve the management of bone metastases in 
China, the Chinese Anti-Cancer Association and the 
Professional Committee of Cancer Rehabilitation and 
Palliative Care together released the Chinese Expert Con-
sensus Statement on the clinical diagnosis and treatment 
of bone metastases in 2007 [16], with an updated ver-
sion released in 2014 [17]. As diagnostic and therapeutic 
guidelines for Chinese clinicians, the Expert Consensus 
Statement presented specific recommendations for diag-
nosing and managing bone metastases. In the statement, 
each treatment option for bone metastases, including 
analgesia, radiotherapy, surgery, and supportive treat-
ment, was reviewed in detail. In particular, the statement 
fully recognized the effectiveness and long-term safety 
of BPs and recommended that BP treatment should start 
as soon as bone metastases is diagnosed and last longer 
than 6  months if the patients tolerate the treatment. 
However, there are very few reports on the frequency 
of BP application and its associated clinical outcomes in 
China.
To identify the characteristics of bone metastasis man-
agement in China and the underlying factors that affect 
the clinical outcomes, we conducted a retrospective epi-
demiologic survey in more than 50 hospitals throughout 
the country. By documenting the types of cancer, sites of 
bone metastases, SRE occurrence, diagnostic methods, 
and treatment of bone metastases, we expected to pro-
vide a database on the local patterns of bone metastasis 
management and provide evidence for the effect of BPs 
on bone metastases in Chinese patients.
Patients and methods
Patients
The participants in this study were consecutively 
recruited from 53 hospitals in 30 Provinces in China 
between January 2008 and August 2009. The patient 
inclusion criteria were as follows: diagnosis of cancer, 
presence of bone metastases, and receiving BP treatment 
for bone metastases at the time of enrollment. The pro-
tocol was approved by the institutional review boards at 
each participating institution. All patients provided writ-
ten informed consent.
Survey design
In the present study, a questionnaire (Additional file  1) 
was developed to collect the information. The question-
naires were completed by physicians with the consent of 
each patient. Using this questionnaire, we collected the 
patients’ basic clinical and demographic data, including 
age, gender, Eastern Cooperative Oncology Group per-
formance status (ECOG PS) score, primary tumor type 
and stage, date of initial cancer diagnosis, and treatment 
for the primary tumor. The questionnaire also collected 
information on the diagnosis and management of bone 
metastases, including the date of the initial bone metas-
tasis diagnosis, diagnostic tests for bone metastases, 
sites of bone metastases, treatments for bone metasta-
ses, number and types of SREs before and after the initial 
bone metastasis diagnosis, date of first SRE, date of first 
BP treatment, duration of BP treatment, types and dos-
age of BPs, and adverse effects during BP treatment. The 
physicians were asked to provide anonymous answers 
regarding their awareness of the Chinese Expert Consen-
sus Statement on the clinical diagnosis and treatment of 
malignant tumor bone metastasis and bone-related dis-
eases, as well as their knowledge on the use of BPs for the 
management of bone metastases.
Statistical analyses
The baseline characteristics of the patients were deter-
mined using descriptive statistics. The quantitative vari-
ables were analyzed with an independent-sample t test. 
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Pearson’s χ2 test and Fisher’s exact test were used to 
examine the differences in the distributions of the cat-
egorical variables as appropriate. Statistical significance 
was defined as a value of P  <  0.05. SPSS for Windows 
software, version 19.0 (IBM, Chicago, IL, USA) was used 




Between January 2008 and August 2009, 3223 eligible 
patients were enrolled into the study. The patients’ demo-
graphic and clinical characteristics are shown in Table 1. 
The most common cancer types were lung (36.5%), breast 
(30.9%), prostate (8.5%), and gastrointestinal cancers 
(5.7%).
Diagnosis of bone metastases
In this study, the diagnostic methods were documented 
for 2979 patients. To screen for bone metastases, 481 
(16.1%) patients received a radionuclide bone scan, 1793 
(60.2%) received a radionuclide bone scan with further 
imaging tests (X-ray radiography, computed tomogra-
phy, or magnetic resonance imaging), and 688 (23.1%) 
received an imaging examination without a radionuclide 
bone scan. Notably, there were 17 patients (0.6%) whose 
diagnosis was based solely on the symptoms or labo-
ratory results, without either imaging or radionuclide 
evidence.
Sites of bone metastases
Typically, multiple sites were affected by bone metas-
tases. We collected information on the sites of bone 
metastases for 3039 patients, and 2578 (84.8%) of them 
had multiple bone metastases. The information on the 
bone metastatic sites for 184 patients was missing. The 
most common bone metastatic site was the thoracic 
spine (n  =  1702, 56.0%), followed by the lumbar spine 
(n = 1431, 47.1%), ribs (n = 990, 32.6%), pelvis (n = 705, 
23.2%), femur (n = 552, 18.2%), and other sites (n = 469, 
15.4%), such as the humerus and skull.
Occurrence and types of SREs
A total of 745 (23.1%) patents had at least one SRE. The 
SRE frequency was the highest in patients with multiple 
myeloma (41/112, 36.6%), followed by those with lung 
cancer (305/1178, 25.9%), breast cancer (201/996, 20.2%), 
prostate cancer (50/274, 18.2%), and gastrointestinal can-
cer (32/185, 17.3%). The types of SREs in the three most 
common cancers (lung, breast, and prostate cancers) 
are shown in Fig.  1. The frequency of bone irradiation 
was the highest (58.0% for lung cancer patients, 45.3% 
for breast cancer patients, and 48.0% for prostate cancer 
patients) compared with other types of SREs. In patients 
with lung cancer or prostate cancer, the frequency of spi-
nal cord compression (35.4% for lung cancer patients and 
26.0% for prostate cancer patients) was second to that of 
radiotherapy. In patients with breast cancer, however, the 
frequency of pathologic fracture (36.3%) was second to 
that of bone irradiation.
Table 1 Demographic and  clinical characteristics of  the 
3223 patients with bone metastases
ECOG PS Eastern Cooperative Oncology Group performance status
Characteristic Number of patients Percent (%)
Age (years)
 <50 935 29.0
 50–70 1673 51.9
 >70 615 19.1
Gender
 Male 1515 47.0
 Female 1708 53.0
ECOG PS
 0 617 19.1
 1 968 30.0
 ≥2 1638 50.8
Cancer type
 Lung cancer 1178 36.5
 Breast cancer 996 30.9
 Prostate cancer 274 8.5
 Gastrointestinal cancer 185 5.7
 Multiple myeloma 112 3.5
 Others 478 14.8
Metastatic sites other than the bone
 Yes 1882 58.4
















Lung cancer Breast cancer Prostate cancer
Types of SREs
Bone irradiation Spinal cord compression
Pathologic fracture Bone surgery
Hypercalcemia
Fig. 1 Types of skeleton-related events (SREs) in patients with lung, 
breast, or prostate cancer. The frequency of bone irradiation was the 
highest in these patients
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Application of BPs and its association with SREs
According to the inclusion criteria of the survey, all of the 
enrolled patients received BP therapy. The majority of the 
patients (80.1%, n =  2583) were treated with third-gen-
eration BPs, 19.5% (n = 629) received second-generation 
BPs, and only 0.3% (n = 11) received first-generation BPs.
The time at which BP therapy was initiated was docu-
mented for 2994 patients, of which 1363 (45.5%) patients 
received BPs at the same time or within 3 months after 
their diagnosis of bone metastases, whereas 1631 (54.5%) 
patients did not start BP treatment until at least 3 months 
after their diagnosis of bone metastases. Notably, the SRE 
frequency in the former group was significantly lower 
than that in the latter group (4.0% vs. 42.3%, P < 0.05).
Among the 745 patients who had experienced at least 
one SRE, the duration of the BP treatment was known 
for 592 patients. The overall average length of BP treat-
ment was 2.71 months. To investigate the efficacy of BPs 
in delaying SREs, we examined the relationship between 
the duration of BP treatment and the time to the first 
SRE. As shown in Fig. 2, the interval between the diag-
nosis of bone metastases and the first SRE increased as 
the BP treatment duration increased. In patients whose 
BP treatment persisted for 6 months or longer, the mean 
time to the first SRE was significantly longer than that of 
the patients who had less than 6 months of BP treatment 
(7.2 vs. 3.4 months, P < 0.05).
Physicians’ awareness of the consensus and knowledge 
on the use of BPs
A total of 740 physicians responded to the questions in 
our questionnaire. Approximately 10.3% of the physicians 
claimed they did not use the Chinese Expert Consensus 
Statement as their clinical guideline for the treatment of 
bone metastases. Additionally, 12.2% of the physicians 
were not aware of the efficacy of BPs in preventing and 
delaying SREs in patients with bone metastases. Nota-
bly, only half of the physicians (52.3%) agreed that the BP 
treatment should persist for at least 6 months unless the 
treatment was intolerable.
Discussion
In this survey, we found that the most common cancer 
type with bone metastases was lung cancer, the most fre-
quently affected bone metastatic sites were the axial skel-
etons, and irradiation to the bone was the most frequent 
SRE in Chinese patients. We also found that the delayed 
initiation and non-persistent use of BP treatment were 
common in China, which significantly increased the risk 
of SREs. Furthermore, Chinese clinicians’ awareness of 
the guidelines and knowledge on bone metastasis man-
agement were not as good as expected, which might lead 
to inappropriate applications of BPs.
Although it has been reported that the bone metastasis 
rate in breast or prostate cancer patients was higher than 
that in lung cancer patients [3, 18, 19], the most common 
cancer type with bone metastases in this survey was lung 
cancer. This result can be explained by that the incidence 
of lung cancer is higher than those of breast and pros-
tate cancers both worldwide [1] and in China [20]. Con-
sistent with previous studies [2, 15], the axial skeletons 
were frequently affected by bone metastases in our sur-
vey. SREs are more likely to occur in the axial skeletons 
than in the peripheral bones and are associated with the 
loss of mobility and social functioning, a decrease in the 
patients’ QoL, and a substantial increase in medical costs. 
Furthermore, SREs can increase the mortality of patients 
with bone metastases. According to a large cohort study 
in Denmark, the 5-year survival rate was 8.3% for breast 
cancer patients suffering from bone metastases without 
SREs; in contrast, the rate was only 2.5% for those with 
both bone metastases and SREs [21]. A similar study of 
9746 prostate cancer patients with bone metastases con-
ducted in the United States also found that the mortality 
was significantly higher in those with both bone metas-
tases and SREs than in those with bone metastases, but 
no SREs [22]. These findings highlight the importance of 
managing bone metastases from the time of diagnosis to 
reduce the risk of SREs.
In our study, 76.3% of the patients received a radio-
nuclide bone scan to screen for bone metastases, and 
16.1% of the patients were diagnosed with bone metas-
tases solely based on the radionuclide bone scan results, 
without confirmation by additional imaging techniques. 
Although the bone scan is a relatively sensitive and inex-





























Fig. 2 Relationship between the duration of bisphosphonate (BP) 
treatment and the time to the first occurrence of SREs. Column, aver-
age value; bar, standard deviation
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its false positive rate is very high, ranging from 30% to 
40% [23, 24]. Thus, the guidelines recommend that posi-
tive findings in the bone scan should be confirmed by 
X-ray radiography, magnetic resonance imaging (MRI), 
computed tomography (CT) scan, or positron emission 
tomography-computed tomography (PET-CT) [13, 15, 
16]. Furthermore, the diagnosis for 17 patients (0.6%) in 
our study was based solely on their symptoms or labo-
ratory results, without bone scan or imaging evidence. 
These findings suggest that the diagnosis of bone metas-
tases in China should be improved in the future.
Several large prospective clinical trials have demon-
strated that BPs effectively prevent and delay SREs in can-
cer patients with bone metastases [8, 25–27]. However, 
the inappropriate application of BPs would substantially 
compromise their effectiveness. A large retrospective 
study of 2212 breast cancer patients with bone metas-
tases found that the risk of SREs was as high as 47.02% 
in the patients with a delayed initiation of BP treatment 
(more than 2 months after the diagnosis of bone metas-
tases) [28]. Similarly, we showed that the risk of SREs 
was 4.0% in patients with early BP treatment, whereas 
the risk was increased to 42.3% in patients with delayed 
BP treatment. Thus, the European Society for Medical 
Oncology (ESMO) [3], National Comprehensive Cancer 
Network (NCCN) [15], and Chinese guidelines [16] all 
recommend that BP treatment should be initiated once 
malignant bone metastases was confirmed. Moreover, 
the persistent use of BPs is also very important to prevent 
and delay SREs. For example, studies showed that persis-
tent, monthly use of BPs for more than 18  months was 
associated with a 50% lower risk of SREs compared with 
persistent, monthly use of BPs for less than 3 months in 
breast cancer patients with bone metastases [28]. In addi-
tion, even for patients with solid tumors who already 
received BP treatment for at least 2 years, the persistent 
use of BPs for an additional 18  months was associated 
with a lower SRE risk (hazard ratio = 0.42, P = 0.01) [29]. 
Our survey also showed that the persistent use of BPs for 
more than 6 months could significantly prolong the time 
to the first SRE compared with the use of BPs for less 
than 6 months. Therefore, BP treatment should be con-
tinued until it is no longer tolerated by the patient or the 
occurrence of substantial decline in the patient’s general 
performance status [13–16].
Unfortunately, our study showed that the use of BPs in 
China was unsatisfactory. Our survey indicated that more 
than half of the patients did not receive BP treatment as 
soon as bone metastases were diagnosed. Furthermore, 
the majority of the patients received less than 6 months 
of BP treatment, and only 10% of patients received more 
than 6  months of persistent BP treatment. It appeared 
that the delayed initiation of the treatment and its poor 
persistency could be attributed, at least partially, to clini-
cian-associated factors. As indicated in our survey, up to 
12.2% of the physicians were not aware of the efficacy of 
BPs in preventing SREs, and nearly half of the physicians 
did not support the long-term use of BPs. Undoubtedly, 
significant efforts are required to improve the clinicians’ 
awareness of the guidelines and knowledge about bone 
metastasis management.
The limitations of this study should be considered in 
the interpretation of the findings. First, this is a retro-
spective study, and thus the observed associations among 
variables might not be causal. Second, because this study 
only included the bone metastasis patients who received 
BPs, the frequency of BP application in the entire bone 
metastasis population remains to be determined.
Conclusions
In summary, our study described the characteristics of 
bone metastases and its management in Chinese cancer 
patients. The results suggested that prompt and persis-
tent BP treatment is associated with a reduced risk of 
SREs. However, our survey also revealed that the proper 
application of BPs was not as common as expected in 
China. There is an urgent demand to improve clini-
cians’ awareness of applying BPs for bone metastasis 
management.
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